13. REFERENCES
1 American Cancer Society. Cancer facts and Figures 1995. Atlanta: American Cancer Society, 6, 1995.
2 DiSaia P.J., Creasman W.T.: Clinical Gynecologic Oncology. Mosby-Year Book, Inc, pp 282-350, St. Louis, Missouri, 1997.
3 Mant J.W.F.& Vessey M.P.: Ovarian and endometrial cancers. Cancer Surveys Trends in Cancer Incidence and Mortality, vol. 9: 287-307, 1994.
4 Yancik R.: Ovarian cancer: age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer, 71: 517-523, 1993.
5 Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ, Park RC. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol; 9(7):1138-50 1991.
6 van Houwelingen JC, ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Neijt JP. Predictability of the survival of patients with advanced ovarian cancer. J Clin Oncol; 7(6):769-73 1989.
7 Neijt JP, ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Willemse PH, Vermorken JB, van Lindert AC, Heintz AP, Aartsen E, van Lent M, et al. Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer; 27(11):1367-72 1991.
8 Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol; 47(2):159-66 1992.
9 Thigpen T, Brady MF, Omura GA, Creasman WT, McGuire WP, Hoskins WJ, Williams S. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer; 71(2 Suppl):606-14 1993.
10 McGuire W.P., Hoskin W.J., Brady M.F., Kucera P.R., Patridge E.E., Look K.Y., Clarke-Pearson D.L., Davidson M.: Cyclophosphamide and Cisplatin compared with Paclitaxel and cisplatin in Patients with Stage III and IV Ovarian Cancer. N. Engl. J. Med., 334: 1-6, 1996.
11 Ozols R.F., Young R.C.: Ovarian Cancer. Curr. Probl. Cancer, 11: 57-122, 1988.
12 Dauplat J., Ferriere J.P., Gorbinet M., Legros M., Chollet P., Gikaud B., Plagne R.: Second look Laparotomy in managing epithelial ovarian carcinoma. Cancer, 57: 1627-1631, 1986.
13 De Gramont A., Drolet Y., Lavoie A., Painchaud M., Blouin R., Tessier C., Ouellet P.: Adriamycin and cis-platinum in advanced ovarian cancer. Eur. J. Cancer Clin. Oncol., 21: 665-669, 1985.
14 Louie K.G., Ozols R.F., Myers C.E., Ostchega Y., Jenskins J., Howser D., Young R.C.: Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma. J. Clin. Oncol., 4: 1579-1585, 1986.
15 Neijt J.P., ten Bokkel Huinink W.W., Van der Burg M.E., van Oosterom A.T., Willemse P.H., Heintz A.P., van Lent M., Trimbos J.B., Bouma J., Vermoken J.B.: Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs. CHAP-5) in advanced ovarian carcinoma. J. Clin. Oncol., 5: 1157-1168, 1987.
16 Pasmantier M.W., Coleman M., Silver R.T., Perry Ballard W.: Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens. Cancer Treat. Rep., 69: 689-693, 1985.
17 Steiner M., Rubinov R., Borovik R., Cohen Y., Robinson E.: Multimodal approach (surgery, chemotherapy and radiotherapy) in the treatment of advanced ovarian carcinoma. Cancer, 55: 2748-2752, 1985.
18 Wils J., Blijham G., Naus A., Belder C., Boschma F., Bron H., Ceelen T., Eekhout A., von Erp J., Geelen P., Geuns H.V., Hoest J., Hoogland H., Huiskes J., de Koning Gans H., Kornman J., Kruyerer G., Lalisang F., Meulen J.V.D., Moorman P., de Pree N., Stoot J., Tushuizen P., Vreeswijk J., Wals J., Wetzels L., Willebrand D.: Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclosphosphamide in stage III-IV epithelial ovarian carcinoma. J. Clin. Oncol., 4: 1068-1073, 1986.
19 De Gramont A., Drolet Y., Varette C., Louvet C., Gonzalez-Canall G., Krulik M., Cady J., Pigne A., Marpeau L., Barrat J., Gallot D., Malafosse M., Debray J.: Survival after second-look laparotomy in advanced ovarian epithelial cancer. Study of 86 patients. Eur. J. Cancer Clin. Oncol., 25: 451-457, 1989.
20 Gershenson D.M., Copeland L.J., Wharton J.T., Atkinson E.N., Sneige N., Edwards C.L., Rutledge F.N.: Prognosis of surgically determined complete responders in advanced ovarian cancer. Cancer, 5: 1129-1135, 1985.
21 Neijt J.P., ten Bokkel Huinik W.W., Van der burg M.E.L., Van Oosterrom A.T.: Complete remission at laparotomy: still a gold standard in ovarian cancer? Lancet, 1 (8488): 1028, 1986.
22 Griffiths CT: Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42:101–104, 1975.
23 Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM: Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 61:413–420, 1983.
24 Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, et al.: The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170:974 –979, 1994.
25 van der Burg MEL, van Lent M, Buyse M, Koblerska A, Columbo N, Favlli G, et al.: The effect of debulking surgery after induction chemotherapy on the prognosis in advanced ovarian cancer. N Engl J Med 332:629 –634, 1995.
26 Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery Is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: prospective study. Gynecol Oncol 69:103-108, 1998.
27 Heintz APM, van Oostrom AT, Trimbos JBMC, et al.: The treatment of advanced ovarian carcinoma.I. Clinical variables associated with prognosis. Gynecol Oncol 30:348-358, 1988.
28 Le T, Krepart GV, Lotocki RJ, heywood MS. Does debulking surgery improve survival in biologically aggressive ovarian carcinoma. Gynecol Oncol 1997 67:208-214.
29 Venesmaa P, Ylikorkala O: Morbidity and mortality associated in primary and repeat operations for ovarian cancer. Obstet Gynecol 1992 79:168-172.
30 Bertelson K: Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecol Oncol 1990 38:203-209.
31 Eisenkop SM, Spirtos NM, Montag TW, Nalick RH Wang HW. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol 1992 47:203-209.
32 Hoskins WJ: Influence of cytoreductive surgery on progression-free interval and survival in epithelial ovarian cancer. Bailliere’s Clin Obstet Gynecol 1989 3:59-71.
33 LoCoco S, Covens A, Carney M, Franssen E, Dogde R, Rosen B, Osborne R, Kerr I, Buckman R, Soper J, et al.. Does aggressive therapy improve survival in suboptimal stage IIIc/IV ovarian cancer? A Canadian-American comparative study. Gynecol Oncol 1995 Nov;59(2):194-9.
34 Kehoe WA, Harralson AF, Jacisin JJ, Duong TT.Sources of prediction error when using a Bayesian method to evaluate nortriptyline serum concentrations. J Clin Pharmacol 1994 Aug;34(8):842-7.
35 Neijt JP, ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Willemse PH, Heintz AP, van Lent M, Trimbos JB, Bouma J, Vermorken JB, et al.. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced 35 ovarian carcinoma. J Clin Oncol 1987 Aug;5(8):1157-68.
36 Smith JP, Day TG Jr. Rewiew of ovarian cancer at the University of Texas Systems Cancer Center, M.D. Anderson Hospital and Tumor Institute. Am J Obstet Gynecol 1979 Dec 1;135(7):984-93.
37 Neijt JP, ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Vriesendorp R, Kooyman CD, van Lindert AC, Hamerlynck JV, van Lent M, van Houwelingen JC, et al.Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet 1984 Sep 15;2(8403):594-600.
38 Michel G,De iaco P, Castaigne D, El-Hassan MJ, Lobreglio R, Lhomme C, Rey A, Duvillard P: Extensive cytoreductive surgery in advanced ovarian carcinoma. Eur J Gynecol Oncol 18:9-15, 1997.
39 Brand E, Pearlman N.Electrosurgical debulking of ovarian cancer: a new technique using the argon beam coagulator. Gynecol Oncol 1990 Nov;39(2):115-8.
40 Deppe G, Malviya VK, Boike G, Malone JM Jr.Use of Cavitron surgical aspirator for debulking of diaphragmatic metastases in patients with advanced carcinoma of the ovaries. Surg Gynecol Obstet 1989 May;168(5):455-6.
41 Nicklin JL, Copeland LJ, O'Toole RV, Lewandowski GS, Vaccarello L, Havenar LP.Splenectomy as part of cytoreductive surgery for ovarian carcinoma. Gynecol Oncol 1995 Aug;58(2):244-7.
42 Rose PG.The cavitational ultrasonic surgical aspirator for cytoreduction in advanced ovarian cancer. Am J Obstet Gynecol 1992 Mar;166(3):843-6.
43 Benedetti-Panici P, Maneschi F, Scambia G, Cutillo G, Greggi S, Mancuso S. The pelvic retroperitoneal approach in the treatment of advanced ovarian carcinoma. Obstet Gynecol 1996 Apr;87(4):532-8.
44 Potter ME, Partridge EE, Hatch KD, Soong SJ, Austin JM, Shingleton HM.Primary surgical therapy of ovarian cancer: how much and when. Gynecol Oncol 1991 44 Mar;40(3):195-200.
45 Eisenkop SM and Spirtos NM. Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with “biological aggressiveness” and survival? Gynecol Oncol 82:435-441, 2001.
46 Nelson BE, Rosenfield AT, Schwartz PE. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 11:166-172, 1993.
47 Trimble E.L., Adams J.D., Vena D., Hawinks M.J., Friedman M.A., Fisherman J.S., Christian M.C., Canetta R., Onetto N., Hayn R.: Paclitaxel for platinum refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Referral center 9103. J. Clin. Oncol., 11: 2405-2410, 1993.
48 McGuire WP, Rowinsky EK, Rosenshein NB, et al.: Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Annals of Internal Medicine 111(4): 273-279, 1989.
49 Einzig AI, Wiernik PH, Sasloff J, et al.: Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. Journal of Clinical Oncology 10(11): 1748-1753, 1992.
50 Thigpen T, Blessing J, Ball H, et al.: Phase II trial of taxol as second-line therapy for ovarian carcinoma: a Gynecologic Oncology Group study. Proceedings of the American Society of Clinical Oncology 9: A-604, 156, 1990.
51 Kohn EC, Sarosy G, Bicher A, et al.: Dose-intense Taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. Journal of the National Cancer Institute 86(1): 18-24, 1994.
52 Trimble EL, Arbuck SG, McGuire WP: Options for primary chemotherapy of epithelial ovarian cancer: taxanes. Gynecologic Oncology 55(3, Part 2): S114-S121, 1994.
53 Aabo K, Adams M, Adnitt P, et al.: Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. British Journal of Cancer 78(11): 1479-1487, 1998.
54 Piccart MJ, Bertelsen K, James K, et al.: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. Journal of the National Cancer Institute 92(9): 699-708, 2000.
55 Muggia FM, Braly PS, Brady MF, et al.: Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. Journal of Clinical Oncology 18(1): 106-115, 2000.
56 Connelly E, Markman M, Kennedy A, et al.: Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity. Gynecologic Oncology 62(2): 166-168, 1996.
57 du Bois A, Richter B, et al. for the AGO Study Group: Cisplatin/paclitaxel vs carboplatin/paclitaxel as 1st-line treatment in ovarian cancer. Proceedings of the American Society of Clinical Oncology 17: A1395, 361a, 1998.
58 Look K.Y., Muss H.M., Blessing J.Á., Morris M.: A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Am. J. of Clinical Oncol., 18: 19-22, 1995.
59 Lorusso V., Catino A., Leone B., Rabinovich M., Gargano G., Paradiso A., De Lena M.: Carboplatin plus ifosfamide as salvage treatment of epithelial ovarian cancer: a pilot study. J. Clin. Oncol., 11: 1952-1956, 1995.
60 Markman M., Reichman B., Hakes T., Jones W., Lewis J.L.Jr., Rubin S., Almadronesi L., Hoskins W.: Responses to second line cisplatin based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J. Clin. Oncol., 9: 1801-1805, 1991.
61 Stiff P.J., Bayer R., Kerger C., Potkul R.K., Malhotra D., Peace D.J., Smith D., Fisher S.G.: High-dose chemotherapy with autologous transplantation for persistent /relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J. Clin. Oncol., 15: 1309-1317, 1997.
62 ten Bokkel Huinink W.W., Gore M., Carmichael J., Gordon A., Malfetano J., Hudson I., Broom C., Scarabelli C., Dawidson N., Spanczynski M., Bolis G., Malmstrom H., Coleman R., Fields S.C., Heron J.F.: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol., 15: 2183-2193, 1997.
63 Vergote I., Himmelmann A., Frankendal B., Scheistroen M., Vlachos K., Trope C.: Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer. Gynecol. Oncol., 47: 282-286, 1992.
64 Sutton GP, Blessing JA, Homesley HD, et al.: Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group study. Journal of Clinical Oncology 7(11): 1672-1676, 1989.
65 Markman M, Hakes T, Reichman B, et al.: Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. Journal of Clinical Oncology 10(2): 243-248, 1992.
66 Hatch KD, Beecham JB, Blessing JA, et al.: Responsiveness of patients with advanced ovarian carcinoma to tamoxifen: a Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 68(2): 269-271, 1991.
67 Rose PG, Blessing JA, Mayer AR, et al.: Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. Journal of Clinical Oncology 16(2): 405-410, 1998.
68 Muggia FM, Hainsworth JD, Jeffers S, et al.: Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. Journal of Clinical Oncology 15(3): 987-993, 1997.
69 Friedlander M, Millward MJ, Bell D, et al.: A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Annals of Oncology 9(12): 1343-1345, 1998.
70 Lund B, Neijt JP. Gemcitabine in cisplatin-resistant ovarian cancer. Semin Oncol 1996 Oct;23(5 Suppl 10):72-6.
71Bookman MA, Malmstrom H, Bolis G, Gordon A, Lissoni A, Krebs JB, Fields SZ.Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998 Oct;16(10):3345-52.
72 Piver M.S., Recio F.O., Baker T.R., Driscoll D.: Evaluation of survival after Second-Line Intraperitoneal Cisplatin-Based Chemotherapy for Advanced Ovarian. Cancer, 73: 1693-1698, 1994.
73 Phase III Randomized Study of Chemotherapy With or Without Secondary Cytoreductive Surgery in Patients With Recurrent Ovarian Epithelial Cancer (Summary Last Modified 10/2000). EORTC-55963.
74 Williams L. The role of secondary cytoreductive surgery in epithelial ovarian malignancies. Oncology 1992;6;25-32.
75 Morris M., Gershenson D.M., Wharton J.T. Secondary cytoreductive surgery in epithelial ovarian cancer: nonresponders to first line therapy. Gynecol Oncol 1989;33:1-5.
76 Michel G., Zarcas D., Castaigne D., Prade M. Secondary cytoreductive surgery in ovarian cancer. Eur J Surg Oncol,15:201-4, 1989.
77 Ozols RF, Bundy BN, Fowler J, et al.: Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 158). Proceedings of the American Society of Clinical Oncology 18: A-1373, 356a, 1999.
78 Nicoletto MO, Tumolo S, Talamini R, et al.: Surgical second look in ovarian cancer: a randomized study in patients with laparoscopic complete remission--a Northeastern Oncology Cooperative Group-Ovarian Cancer Cooperative Group study. Journal of Clinical Oncology 15(3): 994-999, 1997.
79. Podratz KC, Schray MF, Wieand HS, Edmonson JH, Jefferies JA, Long HJ, Malkasian GD, Stanhope CR, Wilson TO. Evaluation of treatment and survival after positive second-look laparotomy. Gynecol Oncol. 1988 Sep;31(1):9-24.
80. Lippman SM, Alberts DS, Slymen DJ, Weiner S, Aristizabal SA, Luditch A, Davis JR, Surwit EA. Second-look laparotomy in epithelial ovarian carcinoma. Prognostic factors associated with survival duration. Cancer. 1988 Jun 15;61(12):2571-7.
81. Heintz AP, Van Oosterom AT, Trimbos JB, Schaberg A, Van der Velde E, Nooy M. The treatment of advanced ovarian carcinoma (II): interval reassessment operations during chemotherapy. Gynecol Oncol. 1988 Jul;30(3):359-71.
82. Hainsworth JD, Grosh WW, Burnett LS, Jones HW 3rd, Wolff SN, Greco FA. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration. Ann Intern Med. 1988 Feb;108(2):165-70.
83. Hoskins WJ, Rubin SC, Dulaney E, Chapman D, Almadrones L, Saigo P, Markman M, Hakes T, Reichman B, Jones WB, et al. Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma. Gynecol Oncol. 1989 Sep;34(3):365-71.
84. Bertelsen K. Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecol Oncol. 1990 Aug;38(2):203-9.
85. Podczaski E, Manetta A, Kaminski P, Ricelli A, Larson J, DeGeest K, Mortel R. Survival of patients with ovarian epithelial carcinomas after second-look laparotomy. Gynecol Oncol. Jan;36(1):43-7, 1990.
86. Potter ME, Hatch KD, Soong SJ, Partridge EE, Austin JM Jr, Shingleton HM. Second-look laparotomy and salvage therapy: a research modality only? Gynecol Oncol. 1992 Jan;44(1):3-9.
87. Hempling RE, Wesolowski JA, Piver MS. Second-look laparotomy in advanced ovarian cancer: a critical assessment of morbidity and impact on survival. Ann Surg Oncol. 1997 Jun;4(4):349-54.
88. Williams L, Brunetto VL, Yordan E, DiSaia PJ, Creasman WT. Secondary cytoreductive surgery at second-look laparotomy in advanced ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 1997 Aug;66(2):171-8.
89. Gadducci A, Iacconi P, Fanucchi A, Cosio S, Teti G, Genazzani AR. Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer. Anticancer Res. 2000 May-Jun;20(3B):1959-64.
90. Raspagliesi et al. 1999. In press.
91. Obermaier A, Sevelda P. Impact of second look laparotomy and secondary cytoreductive surgery at second-look laparotomy in ovarian cancer patients. Acta Obstet Gynecol Scand. 2001 May;80(5):432-6.
92 Bozzetti F., Vaglini M., Deraco M.: Intraperitoneal hyperthermic chemotherapy in gastric cancer: rationale for a new approach. Tumori, 84: 483-488, 1998.
93 Gomes Portilla A., Deraco M., Sugarbaker P.H.: Clinical Pathway for Peritoneal Carcinomatosis from Colon and Rectal Cancer: Guidelines for Current Practice. Tumori, 83: 725-728, 1997.
94 Koga S., Hamazoe R., Maeta M., Shimizu N., Murakami A., Wakatsuki T.: Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with MMC. Cancer, 61: 232-237, 1988.
95 Yonemura Y., Fujimura T., Fushida S., Takegawa S., Kamata T., Katayama K., Kosaka T., Yamaguchi A., Miwa K., Miyazaki I.: Hyperthermia-chemotherapy combined with cytoreductive surgery for the treatment of gastric cancer with peritoneal dissemination. World J. Surg., 15: 530-536, 1991.
96 Deraco M., Vaglini M., Santinami M., Santoro N., Inglese M.G., Spatti G.B.: Intraperitoneal hyperthermic perfusion (IPHP): Analysis of morbidity and toxicity. Oncol. Rep., 3: 1103-1106, 1996.
97 Stephens AD, Alderman R, Chang D, Edwards GD, Esquivel J, Sebbag G, Steves MA, Sugarbaker PH. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol. 1999 Dec;6(8):790-6.
98 Jacquet P, Stephens AD, Averbach AM, Chang D, Ettinghausen SE, Dalton RR, Steves MA, Sugarbaker PH. Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer. 1996 Jun 15;77(12):2622-9.
99 Kober F., Heiss A., Roka R.: Diffuse and gross peritoneal carcinomatosis treated by intraperitoneal hyperthermic chemoperfusion. Cancer Treat. Res., 82: 211-219, 1996.
100 Salle B., Gilly F.N., Carry P.Y., Sayag A., Brachet A., Braillon G.: Intraperitoneal chemo-hyperthermia in the treatment of peritoneal carcinomatosis of ovarian origin. Initial cases, physiopathologic data. J. Gynecol. Obstet. Biol. Reprod., (Paris) 22: 369-371, 1993.
101 Vaart P.J.M., Vange N., Zoetmulder F.A.N., Goethem A.R., Tellingen O., ten Bokkel Huinink W.W., Beijnen J.H., Bartelink H., Begg A.C.: Intraperitoneal Cisplatin with Regional Hyperthermia in Advanced Ovarian Cancer: Pharmacokinetics and Cisplatin-DNA Adduct Formation in patients and Ovarian Cancer Cell Lines. Eur. J. Cancer., 34: 148-154, 1998.
102 Deraco M., Rossi C.R., Pennacchioli E., Guadagni S., Somers D.C., Santoro N., Raspagliesi F., Kusamura S., Vaglini M. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study. Tumori, 87(3):120-126, 2001.
103 Sugarbaker P.H. Peritonectomy procedures. Annals of surgery, 221(1):29-42, 1995.
104 Longo D.L., Young R.C.: The natural history and treatment of ovarian cancer. Review. Annu. Ver. Med., 32: 475-490, 1981.
105 Deraco M., Santoro N., Carraro O., Inglese M.G., Rebuffoni G., Guadagni S., Carlier Somers D., Vaglini M.: Peritoneal Carcinomatosis: Features of dissemination. Review. Tumori, 85: 1-5, 1999.
106 Markman M.: Intraperitoneal cisplatin and carboplatin in the management of ovarian cancer. [Review]. Semin. Oncol., 21(2 supp.2): 17-19, quiz 20, 58, 1994.
107 Sugarbaker P.H., Graves T., De Bruijn E.A., Cunliffe W.J., Mullins R.E., Hull W.E., Oliff L., Schlag P.: Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis form gastrointestinal cancer: pharmacological studies. Cancer Res., 50: 5790, 1990.
108 Alberts D.S., Liu P.Y., Hannigan E.V., et al: Phase III study of intraperitoneal (IP) cisplatin (CDDP)/intravenous (IV) cyclophosphamide (CPA) in patients with optimal disease stage III ovarian cancer: A AWOG-GOG-ECOG Intergroup study. Proc. ASCO, 14: 273 [Abstract], 1995.
109 Los G, McVie JG. Experimental and clinical status of intraperitoneal chemotherapy. Eur J Cancer 1990; 26: 755-62.
110 Markman M.: Intraperitoneal Chemotherapy. Semin. Oncol., 18: 248-254, 1991.
111 Los G, van Vugt MJ, Pinedo HM. Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br J Cancer 1994;69:235-41.
112 Zakris EL, Derwhist MW, Rivieri JE, Hoopes PJ, Page RL, Oleson JR. Pharmacokinetics and toxicity of intraperitoneal cisplatin combined with regional hyperthermia. J Clin Oncol 1987; 5:1613-20.
113 Engelhardt R.: Hyperthermia and drugs. Recent Results Cancer. Res., 104: 136-203, 1987.
114 Teicher B.A., Kowal C.D., Kennedy K.A., Sartorelli A.C.: Enhancement by hyperthermia of the in vitro citotoxicity of mitomycin C toward hypoxic tumor cells. Cancer Res., 41: 1096-1099, 1981.
115 Hettinga J.V.E., Lemstra W., Meijer C., Dam W.A., Uges D.R.A., Konings A.W.T., Vries E.G.E., Kampinge H.: Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumor cells. Br. J. Cancer, 75: 1735-1743, 1997.

1- 2 - 3 - 4 - 5 - 6 - 7